
Edwards Lifesciences (EW) Stock Forecast & Price Target
Edwards Lifesciences (EW) Analyst Ratings
Bulls say
Edwards Lifesciences has demonstrated strong growth in its key product segments, with TAVR revenues increasing 10.6% year-over-year and TMTT sales surging by 48.3%, driven by adoption of innovative technologies like Pascal and Evoque. The company projects consistent growth moving forward, with expectations of TAVR growing 6-8% and TMTT delivering $740-780 million in revenue for fiscal year 2026, indicating robust demand across its offerings. After strong results in the first half of 2025, Edwards management has enhanced confidence in achieving their previously stated sales growth targets of 8-10% year-over-year, with total expected revenues around $6.4 billion to $6.8 billion.
Bears say
Edwards Lifesciences has demonstrated a negative outlook as evidenced by its miss in adjusted operating margin, which fell to 23.7% compared to the consensus expectation of 25.9%, primarily driven by elevated SG&A expenses. Despite TAVR sales exceeding consensus by $29 million, the overall revenue performance was mixed, with Surgical Structural Heart sales underperforming expectations by approximately $4.5 million. Additionally, potential risks including slow market growth for TAVR, emerging competition, and challenges in gaining traction with new product offerings contribute to concerns regarding the company's ability to sustain revenue growth moving forward.
This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.
Edwards Lifesciences (EW) Analyst Forecast & Price Prediction
Start investing in Edwards Lifesciences (EW)
Order type
Buy in
Order amount
Est. shares
0 shares